Cutler Group’s Evogene EVGN Stock Holding History

Cutler Group’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20	Closed	-$1K	–	5544
2021 Q3	$1K	Sell	20 -520	-96%	-$15.2K	﹤0.01%	5286
2021 Q2	$28K	Buy	540 +10	+2%	+$392	﹤0.01%	3007
2021 Q1	$22K	Buy	+530	New	+$32.8K	﹤0.01%	3131

Other funds holding EVGN

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Cutler Group's EVGN Position: Q1 2024 in Review

Cutler Group sold out of Evogene (EVGN) in Q1 2024, closing a stake of 260 shares — an estimated $2K sold.

Cutler Group first reported a position in EVGN in Q1 2021 and held it in 12 quarters. The position peaked at $81K in Q1 2021. 29 funds tracked by Wall St. Rank hold EVGN as of Q1 2024.

Cutler Group reported no remaining Evogene position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 260 Evogene shares in Q1 2024, an estimated $2K.
Cutler Group first reported a position in Evogene in Q1 2021 and held it in 12 quarters.
Cutler Group's Evogene position peaked at $81K in Q1 2021.
29 funds tracked by Wall St. Rank held Evogene as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.